Longest survival follow-up ever reported for a

据报道，a的生存期最长

Phase III immunotherapy trial in this setting

在这种情况下进行的III期免疫治疗试验

Updated results from the HIMALAYA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) plus Imjudo (tremelimumab) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at five years for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localised treatment..

喜马拉雅III期试验的最新结果显示，阿斯利康的Imfinzi（durvalumab）加Imjudo（tremelimumab）对未接受过全身治疗且不符合局部治疗条件的不可切除肝细胞癌（HCC）患者在五年内表现出持续的，临床上有意义的总生存期（OS）益处。。

These results from HIMALAYA will be presented today at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain (presentation 947MO).

喜马拉雅山的这些结果将于今天在西班牙巴塞罗那举行的2024年欧洲肿瘤内科学会（ESMO）大会上发表（演讲947MO）。

At five years of follow-up, this latest exploratory analysis showed that a single priming dose of Imjudo added to Imfinzi, called the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab), reduced the risk of death by 24% compared to sorafenib (based on a hazard ratio [HR] of 0.76; 95% confidence interval [CI] 0.65-0.89).

在五年的随访中，这项最新的探索性分析显示，与索拉非尼相比，在Imfinzi中加入单次启动剂量的Imjudo，称为STRIDE方案（单次Tremelimumab常规间隔Durvalumab），可将死亡风险降低24%（基于危险比[HR]为0.76；95%置信区间[CI]为0.65-0.89）。

An estimated 19.6% of patients treated with the STRIDE regimen were alive at five years versus 9.4% of those treated with sorafenib..

据估计，接受STRIDE方案治疗的患者中有19.6%在五年内存活，而接受索拉非尼治疗的患者中有9.4%。。

In a subgroup analysis of patients in the trial who achieved disease control, defined as complete or partial response or stable disease, 28.7% of those treated with the STRIDE regimen were alive at five years versus 12.7% of patients treated with sorafenib. In addition, an exploratory analysis of depth of response (DpR) showed that more patients treated with the STRIDE regimen experienced deep responses leading to longer survival compared to sorafenib..

在对试验中达到疾病控制（定义为完全或部分缓解或疾病稳定）的患者进行的亚组分析中，使用STRIDE方案治疗的患者中有28.7%在五年内存活，而索拉非尼治疗的患者中有12.7%存活。此外，对反应深度（DpR）的探索性分析显示，与索拉非尼相比，更多接受STRIDE方案治疗的患者经历了深度反应，导致更长的生存期。。

Lorenza Rimassa, MD, Associate Professor of Medical Oncology, Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy and a lead investigator in the HIMALAYA trial, said: “Treatment with durvalumab plus tremelimumab for patients with advanced liver cancer doubled the overall survival rate at five years, a significant survival advantage over sorafenib that has also become even more pronounced over time.

医学博士洛伦扎·里马萨（Lorenza Rimassa）是意大利米兰Humanitas大学和IRCCS Humanitas研究医院的医学肿瘤学副教授，也是喜马拉雅试验的首席研究员，他说：“用durvalumab加tremelimumab治疗晚期肝癌患者，五年时总生存率翻了一番，这比索拉非尼具有显着的生存优势，随着时间的推移，这种优势也变得更加明显。

These data reinforce the use of this novel dual immunotherapy regimen and are an important milestone for patients with this devastating disease.”.

这些数据加强了这种新型双重免疫治疗方案的使用，对于患有这种毁灭性疾病的患者来说是一个重要的里程碑。”。

Sarah Manes, Liver Cancers Program Director at Global Liver Institute, said: “Reaching the five-year survival milestone is both clinically significant and emotionally meaningful for people with advanced liver cancer and their families. We are thrilled to see this progress in improving outcomes with new treatment options, bringing new hope for long-term survivorship to patients in our community.”.

全球肝脏研究所（Global Liver Institute）肝癌项目主任莎拉·曼斯（Sarah Manes）表示：“达到五年生存里程碑，对晚期肝癌患者及其家属来说，具有临床意义和情感意义。我们很高兴看到这一进展在通过新的治疗方案改善预后方面取得了进展，为我们社区患者的长期生存带来了新的希望。”。

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “It is remarkable to see nearly 20 per cent of patients with advanced liver cancer treated with the STRIDE regimen alive at five years compared to only about seven per cent of patients living that long historically. This is a major step forward, setting a new survival benchmark.

阿斯利康肿瘤研发执行副总裁苏珊·加尔布雷斯（SusanGalbraith）表示：“值得注意的是，近20%接受STRIDE方案治疗的晚期肝癌患者在五年内仍然存活，而只有约7%的患者存活了这么长的历史。这是向前迈出的重要一步，确立了新的生存基准。

This underscores our commitment to following patients for the long term to help us better characterise the enduring clinical benefits of this innovative priming approach with an anti-CTLA-4 antibody added to PD-L1 blockade.”.

这强调了我们对长期跟踪患者的承诺，以帮助我们更好地表征这种创新引发方法的持久临床益处，并将抗CTLA-4抗体添加到PD-L1阻断剂中。”。

Summary of updated survival results: HIMALAYA

最新生存结果摘要：喜马拉雅

OSi, ii

OSi，ii

​STRIDE

​跨步

(n=393)

（n=393）

Sorafenib

索拉非尼

(n=389)

（n=389）

​Median duration of follow-up, in months (95% CI)

​中位随访时间，以月为单位（95%置信区间）

​62.5 (59.5-64.8)

​62.5 (59.5-64.8)

59.9 (58.3-61.5)

59.9 (58.3-61.5)

​OS HR (95% CI)

​操作系统HR（95%置信区间）

0.76 (0.65-0.89)

0.76 (0.65-0.89)

p-value (2-sided)iii

p值（双面）iii

0.0008

0.0008

​OS rateiv at 60 months (95% CI), %

60个月时的OS率（95%置信区间），%

19.6

19.6

9.4

9.4

DC at 60 months

60个月DC

Number of patients

患者人数

OS rate, %

操作系统速率，%

43

43

28.7

28.7

17

17

12.7

12.7

DpRv >75% at 60 months

60个月时DpRv>75%

Number of patients

患者人数

OS rateiv, %

OS比率，%

27

27

72.7

72.7

3

3

33.3

33.3

DpRv >50%–≤75% at 60 months

60个月时DpRv>50%–≤75%

Number of patients

患者人数

OS rateiv, %

OS比率，%

34

34

57.8

57.8

12

12

32.1

32.1

i. Updated analysis data cut-off: 01 March 2024, with 82% OS data maturity

i、 更新的分析数据截止日期：2024年3月1日，操作系统数据成熟度为82%

ii. OS HRs and 95% CIs were calculated using a Cox proportional hazards model adjusting for treatment, aetiology, ECOG performance status, and macrovascular invasion

二。使用Cox比例风险模型计算OS HR和95%CI，该模型针对治疗，病因，ECOG表现状态和大血管侵犯进行了调整

iii. Nominal p-value

iii.标称p值

iv. OS rates at 60 months were estimated using Kaplan-Meier methodv. DpR represents the percentage of tumor shrinkage from baseline observed at the time of best objective response evaluation

iv.使用Kaplan-Meier方法估计60个月的OS率。DpR代表在最佳客观反应评估时观察到的肿瘤从基线缩小的百分比

The safety profile of the STRIDE regimen was consistent with the known profiles of each medicine, and no new safety signals were observed with longer follow-up. Serious treatment-related adverse events, defined as Grade 3 or 4 and including death, were experienced by 17.5% of patients treated with the STRIDE regimen versus 9.9% of patients treated with sorafenib, with no new events occurring after the primary analysis for STRIDE..

STRIDE方案的安全性与每种药物的已知特征一致，并且在更长的随访时间内没有观察到新的安全信号。STRIDE方案治疗的患者中有17.5%经历了严重的治疗相关不良事件，定义为3级或4级，包括死亡，而索拉非尼治疗的患者中有9.9%，在STRIDE初步分析后没有发生新事件。。

Imfinzi in combination with Imjudo is approved for the treatment of adults with advanced or unresectable HCC in the US, EU (in the 1st-line setting), Japan and several other countries. Imfinzi monotherapy is also approved in Japan in this setting.

Imfinzi联合Imjudo在美国、欧盟（一线）、日本和其他几个国家被批准用于治疗晚期或不可切除的HCC成人。在这种情况下，日本也批准了Imfinzi单一疗法。

Notes

注意事项

Liver cancer

肝癌

Liver cancer, of which HCC is the most common type, is the third-leading cause of cancer death, with nearly 900,000 people worldwide diagnosed each year and a high prevalence in certain regions of Asia.1-2 An estimated 80-90% of all patients with HCC also have cirrhosis. Chronic liver diseases such as cirrhosis are associated with inflammation that over time can lead to the development of HCC.3.

肝癌是最常见的类型，是癌症死亡的第三大原因，全世界每年诊断出近90万人，在亚洲某些地区患病率很高.1-2估计80-90%的所有HCC患者也有肝硬化。肝硬化等慢性肝病与炎症有关，随着时间的推移，炎症可导致HCC的发展。

Advanced-stage HCC prognosis is poor, with a five-year survival rate of only 7%.4 More than half of patients are diagnosed at advanced stages of the disease, often when symptoms first appear.5 The unique immune environment of liver cancer provides clear rationale for investigating medications that harness the power of the immune system to treat HCC.5.

晚期HCC预后较差，五年生存率仅为7%[4]。超过一半的患者被诊断为疾病的晚期，通常在症状首次出现时[5]。肝癌独特的免疫环境为研究利用免疫系统治疗HCC的药物提供了明确的理论基础。

HIMALAYA

喜马拉雅山

HIMALAYA is a randomised, open-label, multi-centre, global Phase III trial of Imfinzi monotherapy and a regimen comprising a single priming dose of Imjudo 300mg added to Imfinzi 1500mg followed by Imfinzi every four weeks (STRIDE regimen) versus sorafenib, a standard-of-care multi-kinase inhibitor.

喜马拉雅是一项针对Imfinzi单药治疗的随机，开放标签，多中心，全球III期临床试验，该方案包括单次启动剂量的Imjudo 300mg加入Imfinzi 1500mg，然后每四周加入Imfinzi（STRIDE方案）与索拉非尼（一种标准护理多激酶抑制剂）。

The trial included a total of 1,324 randomised patients with unresectable, advanced HCC who had not been treated with prior systemic therapy and were not eligible for locoregional therapy (treatment localised to the liver and surrounding tissue).

该试验共纳入1324名不可切除的晚期HCC患者，这些患者未接受过全身治疗，也不符合局部治疗（治疗局限于肝脏和周围组织）。

The trial was conducted in 181 centres across 16 countries, including in the US, Canada, Europe, South America and Asia. The primary endpoint was OS for the combination versus sorafenib and key secondary endpoints included OS for Imfinzi versus sorafenib, objective response rate and progression-free survival (PFS) for the combination and for Imfinzi alone..

该试验在美国、加拿大、欧洲、南美和亚洲等16个国家的181个中心进行。主要终点是联合用药与索拉非尼的OS，主要次要终点包括Imfinzi与索拉非尼的OS，联合用药和单独使用Imfinzi的客观缓解率和无进展生存期（PFS）。。

Imfinzi

鱼

Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.

Imfinzi（durvalumab）是一种人类单克隆抗体，与PD-L1蛋白结合，阻断PD-L1与PD-1和CD80蛋白的相互作用，对抗肿瘤的免疫逃避策略，释放对免疫反应的抑制作用。

Imfinzi is approved in combination with chemotherapy (gemcitabine plus cisplatin) in locally advanced or metastatic biliary tract cancer (BTC) and in combination with Imjudo (tremelimumab) in unresectable HCC. Imfinzi is also approved as a monotherapy in unresectable HCC in Japan and the EU and in combination with chemotherapy (carboplatin plus paclitaxel) followed by Imfinzi monotherapy in primary advanced or recurrent endometrial cancer that is mismatch repair deficient in the US..

Imfinzi被批准与化疗（吉西他滨加顺铂）联合治疗局部晚期或转移性胆道癌（BTC），并与Imjudo（tremelimumab）联合治疗不可切除的HCC。Imfinzi在日本和欧盟也被批准为不可切除的HCC的单一疗法，并与化疗（卡铂加紫杉醇）联合使用，然后在美国错配修复缺陷的原发性晚期或复发性子宫内膜癌中使用Imfinzi单一疗法。。

In addition to its indications in gastrointestinal (GI) cancers, Imfinzi is the global standard of care in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiotherapy. Imfinzi is also approved for the treatment of extensive-stage small cell lung cancer (SCLC) and in combination with a short course of Imjudo and chemotherapy for the treatment of metastatic NSCLC.

除了胃肠道（GI）癌症的适应症外，Imfinzi是放化疗后疾病未进展的患者无法切除的III期非小细胞肺癌（NSCLC）治疗意图设定的全球护理标准。Imfinzi还被批准用于治疗广泛期小细胞肺癌（SCLC），并结合短期的Imjudo和化疗治疗转移性NSCLC。

In limited-stage SCLC, Imfinzi demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of OS and PFS compared to placebo in patients who had not progressed following standard-of-care concurrent chemoradiotherapy in the ADRIATIC Phase III trial..

在有限期SCLC中，与安慰剂相比，在亚得里亚海III期试验中，在标准治疗同步放化疗后未取得进展的患者中，Imfinzi在OS和PFS的双重主要终点方面表现出统计学上显着且临床上有意义的改善。。

Imfinzi in combination with neoadjuvant platinum-containing chemotherapy before surgery and as adjuvant monotherapy after surgery has been approved for patients in the US and several other countries for the treatment of adult patients with resectable NSCLC and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements..

Imfinzi联合术前新辅助含铂化疗和术后辅助单药治疗已被美国和其他几个国家的患者批准用于治疗可切除的NSCLC且无已知表皮生长因子受体突变或间变性淋巴瘤激酶重排的成年患者。。

Imfinzi plus chemotherapy followed by Imfinzi alone was recently approved in the US for mismatch repair deficient patients with primary advanced or recurrent endometrial cancer. This regimen was also approved in the EU, in addition to Imfinzi plus chemotherapy followed by Imfinzi and Lynparza (olaparib) for mismatch repair proficient patients..

Imfinzi加化疗，然后单独使用Imfinzi，最近在美国被批准用于原发性晚期或复发性子宫内膜癌的错配修复缺陷患者。除了Imfinzi加化疗，然后是Imfinzi和Lynparza（olaparib）治疗错配修复熟练的患者外，该方案也在欧盟获得批准。。

In muscle-invasive bladder cancer, Imfinzi in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival and the key secondary endpoint of OS versus neoadjuvant chemotherapy in the NIAGARA Phase III trial..

在肌肉浸润性膀胱癌中，Imfinzi联合化疗在尼亚加拉III期试验中显示，与新辅助化疗相比，无事件生存的主要终点和OS的关键次要终点有统计学意义和临床意义的改善。。

Since the first approval in May 2017, more than 220,000 patients have been treated with Imfinzi. As part of a broad development programme, Imfinzi is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with SCLC, NSCLC, bladder cancer, breast cancer, several GI and gynaecologic cancers and other solid tumours..

自2017年5月首次批准以来，已有超过220000名患者接受了Imfinzi治疗。作为广泛发展计划的一部分，Imfinzi正在作为单一疗法进行测试，并与其他抗癌疗法联合用于小细胞肺癌，非小细胞肺癌，膀胱癌，乳腺癌，几种胃肠道和妇科癌症以及其他实体瘤患者。。

Imjudo

伊姆柔道

Imjudo (tremelimumab) is a human monoclonal antibody that targets the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Imjudo blocks the activity of CTLA-4, contributing to T-cell activation, priming the immune response to cancer and fostering cancer cell death. In addition to its approved indications in liver and lung cancers, Imjudo is being tested in combination with Imfinzi across multiple tumour types including locoregional HCC (EMERALD-3), SCLC (ADRIATIC) and bladder cancer (VOLGA and NILE)..

Imjudo（tremelimumab）是一种靶向细胞毒性T淋巴细胞相关蛋白4（CTLA-4）活性的人单克隆抗体。Imjudo阻断CTLA-4的活性，促进T细胞活化，引发对癌症的免疫反应并促进癌细胞死亡。除了已批准的肝癌和肺癌适应症外，Imjudo正在与Imfinzi联合测试多种肿瘤类型，包括局部区域HCC（EMERALD-3），SCLC（亚得里亚海）和膀胱癌（伏尔加和尼罗河）。。

AstraZeneca in GI cancers

阿斯利康在胃肠道癌症中的应用

AstraZeneca has a broad development programme for the treatment of GI cancers across several medicines and a variety of tumour types and stages of disease. In 2022, GI cancers collectively represented approximately 4.9 million new cancer cases leading to approximately 3.3 million deaths.6

阿斯利康有一个广泛的发展计划，用于治疗多种药物和各种肿瘤类型和疾病阶段的胃肠道癌症。2022年，胃肠道癌症总计约490万例新发癌症病例，导致约330万人死亡。6

Within this programme, the Company is committed to improving outcomes in gastric, liver, biliary tract, oesophageal, pancreatic and colorectal cancers.

在该计划中，该公司致力于改善胃癌，肝癌，胆道癌，食道癌，胰腺癌和结直肠癌的预后。

In addition to its indications in BTC and HCC, Imfinzi is being assessed in combinations, including with Imjudo, in liver, oesophageal and gastric cancers in an extensive development programme spanning early to late-stage disease across settings.

除了在BTC和HCC中的适应症外，Imfinzi正在一项广泛的发展计划中进行联合评估，包括与Imjudo联合评估肝癌，食道癌和胃癌，该计划涵盖了各个地区的早期至晚期疾病。

The Company is also assessing rilvegostomig (AZD2936), a PD-1/TIGIT bispecific antibody, in combination with chemotherapy as an adjuvant therapy in BTC and as a 1st-line treatment in patients with HER2-negative, locally advanced unresectable or metastatic gastroesophageal junction cancers.

该公司还评估了PD-1/TIGIT双特异性抗体rilvegostomig（AZD2936），联合化疗作为BTC的辅助治疗，以及作为HER2阴性，局部晚期不可切除或转移性胃食管连接癌患者的一线治疗。

Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate, is approved in the US, China and several other countries for HER2-positive advanced gastric cancer and is being assessed in colorectal cancer. It also has been assessed in multiple GI settings including BTC in the DESTINY-PanTumor02 Phase II trial, and it was recently approved in the US for the treatment of unresectable or metastatic HER2-positive solid tumours who have received prior systemic treatment and have no satisfactory alternative treatment options.

Enhertu（曲妥珠单抗-德鲁替康）是一种HER2导向的抗体-药物偶联物，在美国，中国和其他几个国家被批准用于HER2阳性的晚期胃癌，正在结直肠癌中进行评估。在DESTINY-PanTumor02 II期试验中，它也在包括BTC在内的多种胃肠道环境中进行了评估，最近在美国被批准用于治疗先前接受过全身治疗且没有令人满意的替代治疗选择的不可切除或转移性HER2阳性实体瘤。

Enhertu is jointly developed and commercialised by AstraZeneca and Daiichi Sankyo..

Enhertu由阿斯利康和第一三共共同开发和商业化。。

Lynparza (olaparib), a first-in-class PARP inhibitor, is approved in the US, EU and several other countries for the treatment of BRCA-mutated metastatic pancreatic cancer. Lynparza is developed and commercialised in collaboration with MSD (Merck & Co., Inc. inside the US and Canada).

Lynparza（olaparib）是一种一流的PARP抑制剂，在美国，欧盟和其他几个国家被批准用于治疗BRCA突变的转移性胰腺癌。。

AstraZeneca is advancing multiple modalities that provide complementary mechanisms for targeting Claudin 18.2, a promising therapeutic target in gastric cancer. These include AZD0901, a potential first-in-class antibody drug conjugate licensed from KYM Biosciences Inc., currently in Phase III development; AZD5863, a novel Claudin 18.2/CD3 T-cell engager bispecific antibody licensed from Harbour Biomed in Phase I development; and AZD6422, an armoured autologous chimeric antigen receptor T cell (CAR-T) therapy, currently being evaluated in an Investigator Initiated Trial (IIT) in collaboration with AbelZeta in China..

阿斯利康正在推进多种方式，为靶向Claudin 18.2提供补充机制，Claudin 18.2是胃癌的一种有前途的治疗靶点。这些包括AZD0901，一种潜在的一流抗体-药物偶联物，由KYM Biosciences Inc.许可，目前正在进行III期开发；AZD5863是一种新型Claudin 18.2/CD3 T细胞参与者双特异性抗体，在I期开发中从Harbour Biomed获得许可；和AZD6422，一种装甲自体嵌合抗原受体T细胞（CAR-T）疗法，目前正在与AbelZeta在中国合作的研究者发起的试验（IIT）中进行评估。。

In early development, AstraZeneca is developing two Glypican 3 (GPC3) armoured CAR-Ts in HCC. AZD5851, currently in Phase I development, is being developed globally, and C-CAR031 / AZD7003 is being co-developed with AbelZeta in China where it is under evaluation in an IIT.

在早期开发中，阿斯利康正在HCC中开发两种磷脂酰肌醇蛋白聚糖3（GPC3）装甲车。目前处于第一阶段开发的AZD5851正在全球范围内开发，而C-CAR031/AZD7003正在中国与AbelZeta共同开发，目前正在进行IIT评估。

AstraZeneca in immuno-oncology (IO)

阿斯利康免疫肿瘤学（IO）

AstraZeneca is a pioneer in introducing the concept of immunotherapy into dedicated clinical areas of high unmet medical need. The Company has a comprehensive and diverse IO portfolio and pipeline anchored in immunotherapies designed to overcome evasion of the anti-tumour immune response and stimulate the body’s immune system to attack tumours..

阿斯利康是将免疫疗法的概念引入高度未满足医疗需求的专用临床领域的先驱。该公司拥有全面多样的IO投资组合和渠道，以免疫疗法为基础，旨在克服抗肿瘤免疫反应的逃避，并刺激人体免疫系统攻击肿瘤。。

AstraZeneca strives to redefine cancer care and help transform outcomes for patients with Imfinzi as a monotherapy and in combination with Imjudo as well as other novel immunotherapies and modalities. The Company is also investigating next-generation immunotherapies like bispecific antibodies and therapeutics that harness different aspects of immunity to target cancer, including cell therapy and T-cell engagers..

阿斯利康致力于重新定义癌症护理，并帮助将Imfinzi患者的结果转化为单一疗法，并与Imjudo以及其他新型免疫疗法和方式相结合。该公司还正在研究下一代免疫疗法，如双特异性抗体和利用免疫的不同方面来靶向癌症的疗法，包括细胞疗法和T细胞参与者。。

AstraZeneca is pursuing an innovative clinical strategy to bring IO-based therapies that deliver long-term survival to new settings across a wide range of cancer types. The Company is focused on exploring novel combination approaches to help prevent treatment resistance and drive longer immune responses.

阿斯利康正在寻求一种创新的临床策略，将基于IO的疗法引入各种癌症类型的新环境中，以提供长期生存。该公司专注于探索新的组合方法，以帮助预防治疗耐药性并驱动更长的免疫反应。

With an extensive clinical programme, the Company also champions the use of IO treatment in earlier disease stages, where there is the greatest potential for cure..

凭借广泛的临床计划，该公司还倡导在疾病早期阶段使用IO治疗，因为早期疾病具有最大的治愈潜力。。

AstraZeneca in oncology

阿斯利康肿瘤学

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

阿斯利康（AstraZeneca）正在领导一场肿瘤学革命，致力于为各种形式的癌症提供治疗，遵循科学理解癌症及其复杂性，发现、开发并向患者提供改变生命的药物。

The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.

该公司专注于一些最具挑战性的癌症。正是通过不断的创新，阿斯利康建立了行业内最多样化的投资组合和渠道之一，有可能促进医学实践的变化并改变患者的体验。

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

阿斯利康的愿景是重新定义癌症护理，并有一天消除癌症作为死亡原因。

AstraZeneca

阿斯利康

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

阿斯利康（LSE/STO/Nasdaq:AZN）是一家全球科学领先的生物制药公司，专注于肿瘤学，罕见病和生物制药（包括心血管，肾脏和代谢以及呼吸和免疫学）处方药的发现，开发和商业化。

Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca..

阿斯利康的创新药物总部位于英国剑桥，在125多个国家销售，全球数百万患者使用。请访问astrazeneca.com并在社交媒体@astrazeneca上关注该公司。。

Contacts

联系人

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

有关如何联系投资者关系团队的详细信息，请单击此处。有关媒体联系人，请单击此处。

References

参考文献

World Health Organization. Liver Cancer Fact Sheet. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/11-liver-and-intrahepatic-bile-ducts-fact-sheet.pdf. Accessed September 2024.

世界卫生组织。肝癌概况。网址：https://gco.iarc.who.int/media/globocan/factsheets/cancers/11-liver-and-intrahepatic-bile-ducts-fact-sheet.pdf.2024年9月访问。

Liu Y, et al. Changes in the Epidemiology of Hepatocellular Carcinoma in Asia. Cancers (Basel). 2022;14(18):4473.

刘毅等。亚洲肝细胞癌流行病学的变化。癌症（巴塞尔）。2022年；14（18）：4473。

Tarao K, et al. Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases—meta‐analytic assessment. Cancer Med. 2019;8(3):1054-1065.

Tarao K等人。肝硬化对各种肝病中肝细胞癌发展的真正影响荟萃分析评估。癌症医学2019；8（3）：1054-1065。

Sayiner M, et al. Disease Burden of Hepatocellular Carcinoma: A Global Perspective. Digestive Diseases and Sciences. 2019;64: 910-917.​

Sayiner M等人。肝细胞癌的疾病负担：全球视角。消化疾病与科学。2019年；64:910-917

Colagrande S, et al. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol. 2016;22(34):7645-7659.

Colagrande‡S，‡等。晚期肝细胞癌的挑战。‡World J Gastroenterol。‡2016；22（34）：7645-7659。

World Health Organization. Cancer factsheets: Digestive organs (oesophagus, anus, stomach, colon, rectum, liver and intrahepatic bile ducts, pancreas, gallbladder). Available at:  https://gco.iarc.fr/today/en/fact-sheets-cancers. Accessed September 2024.

世界卫生组织。癌症概况：消化器官（食道，肛门，胃，结肠，直肠，肝脏和肝内胆管，胰腺，胆囊）。网址：https://gco.iarc.fr/today/en/fact-sheets-cancers.2024年9月访问。